Table 2.
Clinical characteristics of 46 patients who received dapagliflozin at baseline and after 12 weeks of treatment
| Characteristic | Before treatment | After 12 weeks | P value |
|---|---|---|---|
| BMI (kg/m2) | 26.0 ± 4.85 | 25.9 ± 4.99 | <0.0001 |
| SBP (mmHg) | 131 ± 12.0 | 124 ± 12.6 | <0.0001 |
| DBP (mmHg) | 71.3 ± 10.9 | 70.5 ± 11.1 | 0.5383 |
| FPG (mg/dl) | 139 ± 18.1 | 123 ± 16.9 | <0.0001 |
| HbA1c (%) | 7.72 ± 0.925 | 7.22 ± 0.730 | <0.0001 |
| AST (IU/l) | 23.8 ± 13.2 | 22.4 ± 9.26 | 0.3315 |
| ALT (IU/l) | 31.7 ± 21.1 | 27.9 ± 16.1 | 0.0447 |
| GGT (IU/l) | 49.6 ± 34.8 | 44.8 ± 40.6 | 0.0967 |
| LDL-C (mg/dl) | 89.9 ± 20.9 | 91.0 ± 21.4 | 0.6848 |
| HDL-C (mg/dl) | 59.7 ± 18.5 | 60.8 ± 18.9 | 0.4554 |
| TG (mg/dl) | 124 ± 55.1 | 125 ± 58.3 | 0.9411 |
| Creatinine (mg/dl) | 0.667 ± 0.156 | 0.691 ± 0.164 | 0.1541 |
| Uric acid (mg/dl) | 4.94 ± 1.39 | 4.55 ± 1.36 | 0.0101 |
Data are means ± SD
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c hemoglobin A1c, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT γ-glutamyltransferase, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides